Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 5:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo fasted/fed Clear all
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-988 in Healthy Participants

NCT04082481
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-988, TAK-988 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Glendale, California • Millcreek, Utah
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

NCT01359319
View directory record Official record
Conditions
Hereditary Inclusion Body Myopathy (HIBM)
Interventions
Sialic Acid Extended Release (SA-ER) Tablets, Sialic Acid Extended Release (SA-ER) Tables
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Costa Mesa, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2012 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole

NCT04139226
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-11050
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2020 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDG-7500 in Healthy Adults

NCT06011317
View directory record Official record
Conditions
Healthy Subjects
Interventions
EDG-7500, Placebo
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers

NCT04795037
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
CU06-1004, Single dose, CU06-1004, Multiple doses, Placebo
Drug
Lead sponsor
Curacle Co., Ltd.
Industry
Eligibility
19 Years to 55 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Dose Study in Japanese

NCT01744379
View directory record Official record
Conditions
Gout
Interventions
Lesinurad, Placebo
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
20 Years to 55 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 27, 2026, 5:30 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671

NCT07815678
View directory record Official record
Conditions
Obesity
Interventions
ACCG-2671, Placebo
Drug
Lead sponsor
Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
25 Years to 75 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
6
States / cities
Cypress, California • Lake Forest, California • Decatur, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetic Study of S-Equol in Healthy Volunteers

NCT00787007
View directory record Official record
Conditions
Healthy
Interventions
S-equol, Placebo
Drug
Lead sponsor
Ausio Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

NCT02185794
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Voxilaprevir, Placebo to match voxilaprevir, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Costa Mesa, California • DeLand, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects

NCT01475981
View directory record Official record
Conditions
Healthy
Interventions
JTK-853 or Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2011 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect

NCT02071121
View directory record Official record
Conditions
Healthy
Interventions
BIIB061, Placebo, 14C-BIIB061
Drug
Lead sponsor
Biogen
Industry
Eligibility
20 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Evansville, Indiana • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 1, 2015 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDG-15400 in Healthy Adults

NCT07177066
View directory record Official record
Conditions
Healthy Adults
Interventions
EDG-15400, Placebo
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects

NCT01794364
View directory record Official record
Conditions
Healthy
Interventions
PF-06291874, placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

NCT04536792
View directory record Official record
Conditions
Healthy Volunteers, Anemia, Sickle Cell
Interventions
AG-946, AG-946 Matched Placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
8
States / cities
La Jolla, California • Boston, Massachusetts • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Sep 27, 2026, 5:30 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants

NCT07225517
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB145, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First in Human Trial Evaluating THB335 in Healthy Participants

NCT06425861
View directory record Official record
Conditions
Healthy
Interventions
THB335 single dose, Single dose placebo, THB335 fasted/fed, Placebo fasted/fed, THB335 multiple dose, Multiple dose placebo
Drug
Lead sponsor
Third Harmonic Bio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants

NCT04839809
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-92480, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Multiple Ascending Dose Study of TMP-301 in Healthy Subjects

NCT06025396
View directory record Official record
Conditions
Cocaine Use Disorder, Substance Use Disorders, Healthy Volunteers
Interventions
Cohort 1 - TMP-301, Placebo, Cohort 2 - TMP-301, Cohort 3 - TMP-301, Cohort 4 - TMP-301
Drug
Lead sponsor
Tempero Bio, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease

NCT02323334
View directory record Official record
Conditions
Healthy Volunteers, Alzheimer Disease
Interventions
LY3202626, Placebo (Part A, B, C), Itraconazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649

NCT02151617
View directory record Official record
Conditions
Healthy
Interventions
PF-06743649, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 18, 2015 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of TLL018, With Food Effect, in Healthy Participants

NCT04243083
View directory record Official record
Conditions
Healthy
Interventions
TLL018 tablet, placebo
Drug
Lead sponsor
TLL Pharmaceutical, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Tolerability of E2511 in Healthy Participants

NCT04547361
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2511, E2511 Matched Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of GDC-0310 in Healthy Volunteers

NCT02742779
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GDC-0310, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects

NCT03309241
View directory record Official record
Conditions
Healthy Subjects
Interventions
PF-06882961, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 1, 2018 · Synced Sep 27, 2026, 5:30 AM EDT